Specialty UK pharma company Shield Therapeutics, with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), today announced that Greg Madison has been appointed as chief executive, with effect from Tuesday, June 1, 2021. 28 May 2021
Capsida Biotherapeutics, a US biotech creating a new class of targeted gene therapies using its adeno-associated virus (AAV) engineering and cargo development platform, has named Swati Tole as the company’s first chief medical officer. 12 May 2021
Catherine Owen, senior vice president of major markets at Bristol Myers Squibb, provides an Expert View on why increasing female representation on corporate boards isn’t just a numbers game. Women bring diverse perspectives that are needed more than ever. 7 May 2021
Eikon Therapeutics, a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. 5 May 2021
The European Commission (EC) has granted marketing authorization to ADV7103 (potassium citrate/potassium hydrogen carbonate), proposed trade name Sibnayal, for the treatment of distal renal tubular acidosis (dRTA), says French biotech Advicenne. 4 May 2021
Krakow, Poland-based oncology specialist Ryvu Therapeutics today announced that Vatnak Vat-Ho has joined the company as chief business officer. 26 April 2021
GlaxoSmithKline, the majority shareholder of Galvani Bioelectronic, today announced the termination of Moncef Slaoui as chairman of the Galvani board of directors, effective immediately. 24 March 2021
British clinical stage drug development company Evgen Pharma today announced that Helen Kuhlman will be joining the company as chief business officer, effective April 1, 2021. 22 March 2021
US pharma giant Merck & Co yesterday revealed that Michael Nally, chief marketing officer, Human Health, will leave the company at the end of March, in order to take up a leadership opportunity with another company. 18 March 2021
In a filing with the US Securities and Exchange Commission (SEC), bluebird bio has announced the departure of its chief medical officer, David Davidson. 17 March 2021
Belgium’s AgomAb Therapeutics says it has closed a $74 million Series B financing round led by Redmile Group, which will further advance its lead compound AGMB-101. 10 March 2021
Experienced life sciences leader Bryan Chu Young Kim will strengthen the global leadership team at German drugmaker Stada Arzneimittel as head of global specialties, effective April 1, 2021. 5 March 2021
Kartesia, a European specialist provider of capital solutions for small and mid-sized companies, says it has completed a 12 million-euro ($14.6 million) capital increase in ADL Biopharma has become the sole shareholder of the Spanish biopharmaceutical company, which focuses on the development and production of active pharmaceutical ingredients (APIs) and specialty ingredients. 1 March 2021
Parisian biotech Advicenne has provided a business update, highlighting a recent positive scientific opinion for lead medicine ADV7103 (potassium citrate/potassium hydrogen carbonate) in Europe. 19 February 2021
A new pharmaceutical R&D model was created today, with the merger of 10 privately-held biotech companies with highly validated programs led by industry leading teams to operate under the Centessa umbrella. 17 February 2021
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024